Zolgensma (onasemnogene abeparvovec): Risk for thrombotic microangiopathy

Manufacturers highlight thrombotic microangiopathy (TMA) has been reported. Creatinine and FBC testing is now required before administration, and platelets should be closely monitored a regular basis afterwards. If patients have symptoms of TMA specialist advice should be sought

Source:

Novartis